Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 24, Issue 5, Pages 638-646
Publisher
Springer Nature
Online
2018-04-20
DOI
10.1038/s41591-018-0007-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
- (2017) Monique B. Nilsson et al. Science Translational Medicine
- A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
- (2017) Ji-Youn Han et al. Cancer Research and Treatment
- Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
- (2016) David Planchard et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
- (2016) Hampig Raphael Kourie et al. Expert Opinion on Drug Metabolism & Toxicology
- NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors
- (2016) Mengmeng Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
- (2016) Daniel B. Costa et al. Journal of Thoracic Oncology
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
- (2015) M. G. Kris et al. ANNALS OF ONCOLOGY
- A systematic analysis of the resistance and sensitivity of HER2YVMAreceptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer
- (2015) Xiaokun Shen et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
- (2015) Igor F. Tsigelny et al. Oncotarget
- Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
- (2014) Yook-Hwan Noh et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization
- (2013) J. Cho et al. CANCER RESEARCH
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours
- (2013) Sven Wind et al. CLINICAL PHARMACOKINETICS
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations
- (2013) J. J. Wheler et al. MOLECULAR CANCER THERAPEUTICS
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study
- (2012) Y. Ito et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
- (2011) Yongsheng Wang et al. Therapeutic Advances in Medical Oncology
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
- (2009) S. A. Perera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Paul Wheatley-Price et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started